Kymera Therapeutics, Inc. (KYMR) Financial Statements
Kymera Therapeutics financial statements at a glance
Kymera Therapeutics reported revenue of $39.21 million for fiscal year 2025 (ended December 31, 2025), down 16.7% from fiscal year 2024. Net income was -$311.35 million, a net margin of 794.0% loss.
At the end of fiscal year 2025 it had total assets of $1.74 billion, total liabilities of $163.15 million and shareholders' equity of $1.58 billion, with cash and short-term investments of $848.28 million and total debt of $82.25 million.
Its operations brought in -$232.89 million of cash; capital spending was $1.45 million, leaving free cash flow of -$234.34 million.
The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.
Figures from company filings, in USD; latest fiscal year ended December 31, 2025.
Kymera Therapeutics, Inc.
Income Statement
Annual • USD
Kymera Therapeutics key figures by fiscal year
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $39.2M | $47.1M | $78.6M | $46.8M | $72.8M |
| Operating income | -$345.5M | -$256.7M | -$165.5M | -$161.3M | -$100.5M |
| Net income | -$311.4M | -$223.9M | -$147.0M | -$154.8M | -$100.2M |
| Diluted EPS | – | – | -$2.52 | -$2.87 | -$2.09 |
| Total assets | $1.7B | $978.0M | $575.8M | $603.1M | $605.9M |
| Total liabilities | $163.1M | $142.4M | $180.8M | $113.0M | $146.3M |
| Shareholders' equity | $1.6B | $835.6M | $395.0M | $490.2M | $459.6M |
| Cash and short-term investments | $848.3M | $488.7M | $374.9M | $407.2M | $442.4M |
| Total debt | $82.3M | $87.8M | $84.7M | $17.3M | $18.0M |
| Operating cash flow | -$232.9M | -$194.5M | -$102.8M | -$153.1M | -$128.9M |
| Capital spending | $1.4M | $12.8M | $34.5M | $2.8M | $1.6M |
| Free cash flow | -$234.3M | -$207.3M | -$137.3M | -$155.9M | -$130.5M |
In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2018.
Questions and answers
What was Kymera Therapeutics's revenue in fiscal year 2025?
$39.21 million, down 16.7% from $47.07 million in fiscal year 2024.
How much profit does Kymera Therapeutics make?
Kymera Therapeutics reported net income of -$311.35 million for fiscal year 2025 (794.0% of revenue); operating income was -$345.54 million.
How much cash and debt does Kymera Therapeutics have?
At the end of fiscal year 2025: cash and short-term investments of $848.28 million and total debt of $82.25 million.
What is Kymera Therapeutics's free cash flow?
-$234.34 million in fiscal year 2025 (operating cash flow of -$232.89 million minus capital spending of $1.45 million).
